BETRIXABAN – THE FIRST AND ONLY ORAL ANTICOAGULANT APPROVED FOR VTE
Dr. Haritha Themagepalli*
ABSTRACT
Venous Thromboembolism (VTE) is one of the leading causes of preventable death. Though many drugs are already available for the treatment, all of them were non-oral with severe toxicities in renal and hepatic impaired patients. Betrixaban is a factor Xa inhibitor, orally active drug with unique characteristics like long Half-life, minimal renal excretion, minimal hepatic metabolism. This article provided review on all aspects of Betrixaban including its mechanism of action, its pharmacokinetics, pharmacodynamics, pre-clinical studies, clinical phases of this drug with a note on its safety and efficacy concerns on every phase and comparison with other existing treatments for VTE like Enoxaparin, Warfarin, and the emergence of extended duration thromboprophylaxis and its antidote Andexanet alfa.
[Full Text Article] [Download Certificate]